Abstract: Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Abstract: The technology disclosed herein enables configuration and sharing of a coverage map which displays asset data. In various implementations, an asset owner provides access to select portions of asset data, such as vehicle performance data, to an end-user. The asset owner configures a coverage map to display the selected data according to the type of asset data to be displayed, the scope of the data to be displayed, and other map attributes. Once configured, a URL is generated which the fleet operator provides to the end-user.

Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.

Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.

Abstract: A system receives vehicle metric data from a gateway device connected to a vehicle. The vehicle gateway device gathers data related to operation of the vehicle and/or location data. The system receives data from multiple vehicles and multiple fleets. The system uses machine learning to identify cohorts for fleets. The system calculates metrics for fleets and benchmarks for the cohorts. The system presents the metrics and benchmarks in a graphical user interface.

Abstract: An analytics reporting system to perform operations that include: aggregating sensor data collected from a plurality of sensor devices within a database, the sensor data comprising a set of values that correspond with a metric; generating a threshold value based on the set of values that correspond with the metric; accessing a portion of the sensor data based on an identifier associated with the portion of the sensor data; determining the portion of the sensor data transgresses the threshold value; and generating a report that comprises a display of the portion of the sensor data based on the determining that the portion of the sensor data transgresses the threshold value.

Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.

Abstract: In various implementations, an asset gateway service receives log messages comprising asset data captured by a gateway device associated with an asset. The log messages each include a first identifier corresponding to a first representation of the gateway device, which itself is associated with a first organization. The service persists data from the log to a first datastore accessible by the first organization. The service also determines whether a second representation of the gateway device (i.e., a clone) exists. If so, the service persists at least some of the data from the log message to a second datastore, which itself may be associated with a second organization, thereby allowing both organizations to access the data in a secure yet convenient manner.

Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.

Abstract: An analytics reporting system to perform operations that include: aggregating sensor data collected from a plurality of sensor devices within a database, the sensor data comprising a set of values that correspond with a metric; generating a threshold value based on the set of values that correspond with the metric; accessing a portion of the sensor data based on an identifier associated with the portion of the sensor data; determining the portion of the sensor data transgresses the threshold value; and generating a report that comprises a display of the portion of the sensor data based on the determining that the portion of the sensor data transgresses the threshold value.

Abstract: A system receives vehicle metric data from a gateway device connected to a vehicle. The vehicle gateway device gathers data related to operation of the vehicle and/or location data. The system receives data from multiple vehicles. The vehicle gateway device gathers vehicle metric data and correlates the metric data with location data. The system presents the correlated data in an interactive map graphical user interface.

Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.

Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.

Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.

Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.

Abstract: A system receives vehicle metric data from a gateway device connected to a vehicle. The vehicle gateway device gathers data related to operation of the vehicle and/or location data. The system receives data from multiple vehicles and multiple fleets. The system uses machine learning to identify cohorts for fleets. The system calculates metrics for fleets and benchmarks for the cohorts. The system presents the metrics and benchmarks in a graphical user interface.

Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.

Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.

Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.

Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.